KR20160091350A - 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신 - Google Patents

중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신

Info

Publication number
KR20160091350A
KR20160091350A KR1020167015308A KR20167015308A KR20160091350A KR 20160091350 A KR20160091350 A KR 20160091350A KR 1020167015308 A KR1020167015308 A KR 1020167015308A KR 20167015308 A KR20167015308 A KR 20167015308A KR 20160091350 A KR20160091350 A KR 20160091350A
Authority
KR
South Korea
Prior art keywords
mers
acid sequence
seq
spike
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167015308A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 비. 웨이너
카루피아 무투마니
니란잔 와이. 사르데자이
Original Assignee
더 트러스티스 오브 더 유니버시티 오브 펜실바니아
이노비오 파마수티컬즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 트러스티스 오브 더 유니버시티 오브 펜실바니아, 이노비오 파마수티컬즈, 인크. filed Critical 더 트러스티스 오브 더 유니버시티 오브 펜실바니아
Priority to KR1020237027157A priority Critical patent/KR20230122181A/ko
Publication of KR20160091350A publication Critical patent/KR20160091350A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020167015308A 2013-11-29 2014-11-26 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신 Ceased KR20160091350A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237027157A KR20230122181A (ko) 2013-11-29 2014-11-26 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361910153P 2013-11-29 2013-11-29
US61/910,153 2013-11-29
PCT/US2014/067537 WO2015081155A1 (en) 2013-11-29 2014-11-26 Mers-cov vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237027157A Division KR20230122181A (ko) 2013-11-29 2014-11-26 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신

Publications (1)

Publication Number Publication Date
KR20160091350A true KR20160091350A (ko) 2016-08-02

Family

ID=53199622

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167015308A Ceased KR20160091350A (ko) 2013-11-29 2014-11-26 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신
KR1020237027157A Ceased KR20230122181A (ko) 2013-11-29 2014-11-26 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237027157A Ceased KR20230122181A (ko) 2013-11-29 2014-11-26 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신

Country Status (10)

Country Link
US (5) US10016497B2 (enExample)
EP (1) EP3074051A4 (enExample)
JP (1) JP6412131B2 (enExample)
KR (2) KR20160091350A (enExample)
CN (2) CN112057613A (enExample)
AU (1) AU2014354797C1 (enExample)
CA (1) CA2932055A1 (enExample)
IL (3) IL305392A (enExample)
SA (1) SA516371223B1 (enExample)
WO (1) WO2015081155A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019078600A1 (ko) * 2017-10-19 2019-04-25 (주)에이티젠 중동호흡기증후군 코로나바이러스에 대한 항체 및 이를 이용한 항체역가 측정방법
KR20210136998A (ko) * 2020-05-08 2021-11-17 한림대학교 산학협력단 코로나 바이러스 억제용 펩타이드 및 그 용도

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014134439A1 (en) 2013-03-01 2014-09-04 New York Blood Center, Inc. Immunogenic composition for mers coronavirus infection
KR20160091350A (ko) * 2013-11-29 2016-08-02 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신
US11103575B2 (en) 2014-02-28 2021-08-31 The New York Blood Center, Inc. Immunogenic composition for MERS coronavirus infection
EP3045181B1 (en) * 2015-01-19 2018-11-14 Ludwig-Maximilians-Universität München A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV)
US11058779B2 (en) 2015-09-08 2021-07-13 Sirnaomics, Inc. Sirna/nanoparticle formulations for treatment of middle-east respiratory syndrome coronaviral infection
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
CN106397549B (zh) * 2016-10-11 2019-08-06 中国疾病预防控制中心病毒病预防控制所 MERS-CoV特异性多肽及其应用
WO2018089306A1 (en) 2016-11-10 2018-05-17 Oyagen, Inc. Methods of treating and inhibiting ebola virus infection
KR20180058206A (ko) * 2016-11-23 2018-05-31 에스케이케미칼 주식회사 중동호흡기증후군 코로나바이러스 s 단백질 면역원 조성물 및 이의 제작 방법
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
WO2021158248A1 (en) 2020-02-04 2021-08-12 Oyagen, Inc. Method for treating coronavirus infections
JP2023511780A (ja) 2020-02-25 2023-03-22 イノビオ ファーマシューティカルズ，インコーポレイティド コロナウイルスに対するワクチンおよび使用方法
CN111378785A (zh) * 2020-03-12 2020-07-07 仁宽(上海)生物科技有限公司 用于核酸诊断新型冠状病毒2019-nCov的假病毒标准品及其应用
US11559577B2 (en) 2020-03-31 2023-01-24 Engimata, Inc. Immunogenic composition forming a vaccine, and a method for its manufacture
US20230226170A1 (en) * 2020-05-12 2023-07-20 Greffex, Inc. Engineering coronavirus spike proteins as vaccine antigens, their design and uses
WO2021252604A1 (en) * 2020-06-09 2021-12-16 The Wistar Institute Of Anatomy And Biology Coronavirus disease 2019 (covid-19) combination vaccine
WO2022011332A2 (en) * 2020-07-10 2022-01-13 Engimata, Inc Immunogenic composition forming a vaccine, and a method for its manufacture
WO2022020604A1 (en) * 2020-07-22 2022-01-27 Greffex, Inc. Multivalent beta-coronavirus vaccines, their design and uses
US20230279361A1 (en) * 2020-07-27 2023-09-07 National University Corporation Shiga University Of Medical Science Method for in vitro proliferating virus belonging to family coronaviridae, method for producing neutralizing antibody to virus belonging to family coronaviridae, and method for producing infection model of severe acute respiratory syndrome coronavirus 2
UY39378A (es) * 2020-08-14 2022-01-31 Univ Wuerzburg J Maximilians Vacuna de salmonella para el tratamiento de coronavirus
US20240016919A1 (en) * 2020-08-25 2024-01-18 The Wistar Institute Of Anatomy And Biology INTRADERMAL MERS-CoV VACCINE
US20230349889A1 (en) * 2020-09-10 2023-11-02 The Council Of The Queensland Institute Of Medical Research Methods of Determining Immune Response
AU2021340715A1 (en) * 2020-09-11 2023-04-27 Mark J. Cantwell Enhancing immunity using chimeric cd40 ligand and coronavirus vaccine
US20220370598A1 (en) * 2021-05-05 2022-11-24 Inovio Pharmaceuticals, Inc. Vaccines Against Coronavirus and Methods of Use

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
US3805783A (en) 1971-02-12 1974-04-23 A Ismach Hand powered hypodermic jet injector gun
US4342310A (en) 1980-07-08 1982-08-03 Istvan Lindmayer Hydro-pneumatic jet injector
US4447223A (en) 1982-04-16 1984-05-08 Cct Associates Medicament implant applicator
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5545130A (en) 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5505697A (en) 1994-01-14 1996-04-09 Mckinnon, Jr.; Charles N. Electrically powered jet injector
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6208893B1 (en) 1998-01-27 2001-03-27 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6120493A (en) 1998-01-27 2000-09-19 Genetronics, Inc. Method for the introduction of therapeutic agents utilizing an electroporation apparatus
US6009347A (en) 1998-01-27 1999-12-28 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6302874B1 (en) 1998-07-13 2001-10-16 Genetronics, Inc. Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications
US6192270B1 (en) 1998-08-14 2001-02-20 Genetronics, Inc. Apparatus and method for the delivery of drugs and genes into tissue
US6150148A (en) 1998-10-21 2000-11-21 Genetronics, Inc. Electroporation apparatus for control of temperature during the process
EP1183068A4 (en) 1999-05-10 2008-12-17 Gentronics Inc ENHANCED ACTIVE AGENT DELIVERY METHOD BY ELECTROPORATION
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
US7803918B2 (en) * 2003-08-18 2010-09-28 Amsterdam Institute Of Viral Genomics B.V. Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics
CN101098710A (zh) * 2004-06-02 2008-01-02 纽约血液中心 产生高度有效抗体的sars疫苗和方法
AU2005250477A1 (en) * 2004-06-04 2005-12-15 Wyeth Enhancing protein expression
US7553944B2 (en) * 2004-07-21 2009-06-30 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
JP5852883B2 (ja) * 2008-08-08 2016-02-03 タケダ ワクチン，インコーポレイテッド 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子
CN103476928B (zh) * 2010-12-09 2017-03-29 巴斯德研究所 用于获得高产量重组蛋白表达的基于mgmt的方法
EP2788478B1 (en) * 2011-12-09 2017-08-23 Institut Pasteur Multiplex immuno screening assay
US9555094B2 (en) * 2012-07-23 2017-01-31 The Institute Of Biological Resources Isolated nucleic acid for the production of a vaccine against virus
EP3046579A1 (en) 2013-09-19 2016-07-27 Novavax, Inc. Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods
KR20160091350A (ko) * 2013-11-29 2016-08-02 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019078600A1 (ko) * 2017-10-19 2019-04-25 (주)에이티젠 중동호흡기증후군 코로나바이러스에 대한 항체 및 이를 이용한 항체역가 측정방법
KR20210136998A (ko) * 2020-05-08 2021-11-17 한림대학교 산학협력단 코로나 바이러스 억제용 펩타이드 및 그 용도

Also Published As

Publication number Publication date
WO2015081155A1 (en) 2015-06-04
CA2932055A1 (en) 2015-06-04
AU2014354797B2 (en) 2017-10-26
US20200222527A1 (en) 2020-07-16
AU2014354797A1 (en) 2016-07-07
CN105939730A (zh) 2016-09-14
SA516371223B1 (ar) 2023-01-31
IL245903A0 (en) 2016-07-31
JP2016539946A (ja) 2016-12-22
US20210401972A1 (en) 2021-12-30
IL305392A (en) 2023-10-01
CN112057613A (zh) 2020-12-11
CN105939730B (zh) 2020-09-11
US20190022213A1 (en) 2019-01-24
US11135284B2 (en) 2021-10-05
US10016497B2 (en) 2018-07-10
EP3074051A4 (en) 2017-04-12
US20170258893A1 (en) 2017-09-14
US20240123056A1 (en) 2024-04-18
IL276210A (en) 2020-09-30
IL276210B2 (en) 2024-01-01
KR20230122181A (ko) 2023-08-22
AU2014354797C1 (en) 2018-02-01
IL276210B1 (en) 2023-09-01
JP6412131B2 (ja) 2018-10-24
IL245903B (en) 2020-08-31
US11801298B2 (en) 2023-10-31
EP3074051A1 (en) 2016-10-05
US10548971B2 (en) 2020-02-04

Similar Documents

Publication Publication Date Title
US11801298B2 (en) MERS-CoV vaccine
US11027011B2 (en) Vaccines with biomolecular adjuvants
US10933130B2 (en) Vaccines with interleukin-33 as an adjuvant
KR20170062467A (ko) 항원 및 어쥬번트로서 인터류킨-21을 갖는 백신
KR20170129804A (ko) Cd40 리간드를 어쥬번트로서 갖는 백신
HK40042641A (en) Mers-cov vaccine
US10792358B2 (en) ISG15 and its use as an adjuvant
HK1228285A1 (en) Mers-cov vaccine
HK1228285B (en) Mers-cov vaccine
WO2022046737A1 (en) Intradermal mers-cov vaccine

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160609

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191125

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210503

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211228

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210503

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20211228

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210802

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20191125

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220414

Patent event code: PE09021S01D

AMND Amendment
PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20230309

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20221115

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20220414

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220329

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20211228

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210802

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20210503

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20191125

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20230809

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20230309

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20211228

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2023101001725

Request date: 20230809

J121 Written withdrawal of request for trial
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20240311

PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20240311

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2023101001725

Request date: 20230809

Appeal kind category: Appeal against decision to decline refusal

WITB Written withdrawal of application